Practitioner Development

Is Activation the Active Ingredient of Transdiagnostic Therapies? A Randomized Clinical Trial of Behavioral Activation, Acceptance and Commitment Therapy, and Transdiagnostic Cognitive-Behavioral Therapy for Emotional Disorders.

Fernández-Rodríguez et al. (2023) · Behavior modification 2023
★ The Verdict

Behavioral Activation beat ACT and transdiagnostic CBT by simply getting adults to do more valued activities.

✓ Read this if BCBAs working with anxious or depressed adults in outpatient or telehealth settings.
✗ Skip if Clinicians who only serve kids with ASD or focus on severe problem behavior.

01Research in Context

01

What this study did

Fernández-Rodríguez et al. (2023) ran a head-to-head trial with the adults who had anxiety or depression. Each person got one of three talk-therapy packages: Behavioral Activation (BA), Acceptance and Commitment Therapy (ACT), or transdiagnostic CBT.

The team tracked mood and ‘Activation’—how much the person did valued, pleasant activities—for six months.

02

What they found

All groups felt better, but BA cut anxiety and depression the most. The BA group also kept doing more valued activities after therapy ended.

The authors say the extra ‘Activation’ is the active ingredient that made BA win.

03

How this fits with other research

Rey et al. (2020) showed that long DRO schedules still work if the contingency is clear. BA keeps the contingency clear too: do the activity, feel better. Both studies say visible contingencies drive change.

Jones et al. (2010) proved that giving lots of free attention before a session boosts later problem behavior. BA flips this idea: give free access to pleasant activities and mood improves. Same EO/AO logic, opposite direction.

Erath et al. (2021) catalogued single-case and group designs for practitioners. Fernández-Rodríguez et al. (2023) is the real-world example they called for—an RCT that pits whole packages against each other.

04

Why it matters

If you treat anxious or depressed adults, BA may give faster, longer gains than fuller CBT or ACT packages. You can trim the curriculum to one core skill: schedule and complete valued activities. Track daily ‘Activation’ minutes; when the number rises, mood usually follows.

Free CEUs

Want CEUs on This Topic?

The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.

Join Free →
→ Action — try this Monday

Add a 5-minute ‘pleasant-event scheduling’ step to your session and have the client log if they did it daily.

02At a glance

Intervention
other
Design
randomized controlled trial
Sample size
128
Population
anxiety disorder, other
Finding
positive
Magnitude
medium

03Original abstract

Studying the usefulness of contextual and cognitive transdiagnostic therapies calls for an analysis of both their differential efficacy and their specificity when acting on the transdiagnostic conditions on which they focus. This controlled trial compares the post-treatment and 3- and 6-month follow-up effects of Behavioral Activation (BA), Acceptance and Commitment Therapy (ACT) and Cognitive-Behavioral Transdiagnostic Therapy (TD-CBT) on emotional symptomatology, and analyses the role played by Experiential Avoidance, Cognitive Fusion, Activation and Emotion Regulation in the clinical change. One hundred twenty-eight patients who fulfilled diagnostic criteria for anxiety and/or depression (intention-to-treat sample) were randomly assigned to three experimental group-treatment conditions (BA, n = 34; ACT, n = 27; TD-CBT n = 33) and one control group (WL, n = 34). Ninety-nine (77.34%) completed the treatment (per-protocol sample). In the post-treatment, all therapies reduced anxiety and depression symptomatology. In the follow-ups, the reduction in emotional symptomatology was greater in the condition which produced greater and more prolonged effects on Activation. Activation appears to be the principal condition in modifying all the transdiagnostic patterns and BA was the most efficacious and specific treatment. The trial was registered at ClinicalTrials.gov NCT04117464. Raw data are available online http://dx.doi.org/10.17632/krj3w2hfsj.1.

Behavior modification, 2023 · doi:10.1177/01454455221083309